Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis

Inclusion Criteria: 1. Male or female, aged between 50 to 75; 2. Subjects diagnosed with IPF according to guidelines for the diagnosis of idiopathic pulmonary fibrosis 2018 edition; 3. Subjects with 30%\~79% of the predicted value in diffusing capacity for carbon monoxide (DLCO) in pulmonary function tests 3 months before screening; 4. Subjects with typical High-resolution computed tomography (HR-CT) imaging findings of idiopathic pulmonary fibrosis in the past 12 months; 5. Subjects tolerant to bronchofiberscope; 6. Subjects fully informed of the purpose, method and possible discomfort of the trial, agreeing to participate in the test, and voluntarily signing the informed consent; 7. Subjects with good adherence, willingness to take medication and regular follow-up examinations as required by the protocol; 8. Subjects able to understand and cooperate with the completion of pulmonary function tests. Exclusion Criteria: 1. Subjects who cannot tolerate cell therapy; 2. Pregnant or lactating women; 3. Subjects with syphilis or any of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) positive antibody; Of which stable HBV carriers after drug treatment (DNA titer ≤500 IU/mL or copy number \<1000 copies/mL) and cured hepatitis C patients (HCV RNA is negative) can be enrolled; 4. Subjects with malignant tumors or a history of malignant tumors; 5. Subjects with serious significant pulmonary infection and needing anti-infection treatment; 6. Subjects with taking drugs which caused lung fibroblast such as amiodarone in a long term before screening; 7. Subjects with infections in lung or other site, including bacterial and viral infections, requiring intravenous treatment before cell transplantation; 8. Subjects with a history of invasive or noninvasive mechanical ventilation within 4 weeks; 9. Subjects with any of the following lung diseases: asthma, active tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, pneumoconiosis, etc.; lung cancer, bronchiolitis obliterans or other active lung disease; Pneumonia currently or within the last 4 weeks; Pneumonectomy Previously; 10. Subjects needing oxygen therapy currently (oxygen therapy time\> 15h/d); 11. Subjects suffering from serious other systemic diseases, such as myocardial infarction, unstable angina, liver cirrhosis, acute glomerulonephritis, connective tissue disease, etc.; 12. Subjects with following results : leukopenia (leukopenia \< 4×10\^9/L) or agranulocytosis (leukocyte \< 1.5×10\^9/L or neutrophils \< 0.5×10\^9/L) of any cause; Blood creatinine \> 2.5 times the upper limit of normal; Alanine transaminase (ALT) and Aspartate transaminase (AST) \> 2.5 times the upper limit of normal values in the laboratory tests; 13. Subjects with a history of mental illness or suicide risk, epilepsy or other central nervous system disorders; 14. Subjects with severe arrhythmias (such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or atrioventricular block of degree II or above, shown by 12-lead Electrocardiogram (ECG); 15. Subjects with a history of abusing alcohol and illicit drug; 16. Subjects with serious heart disease \[New York Heart Association (NYHA) class III-IV\]; 17. Subjects who are allergic to cattle products; 18. Subjects who participated in other clinical trials in the past 3 months; 19. Subjects with poor compliance and difficult to complete the investigation; 20. Investigators, employees of research centers or family members of them (none of whom are suitable to participate in the trial to ensure the objectivity of the research); 21. Subjects who had an acute exacerbation of IPF or hospitalized for other respiratory diseases 3 or more times in the past 1 year; 22. Subjects who take nintedanib for medication within 1 month, or plan to continue taking nintedanib for medication; 23. Subjects with other acquired or congenital immunodeficiency disorders, or with a history of organ transplantation or cell transplant therapy; 24. Subjects whose expected survival may be less than one year judged by the investigator; 25. Male participants of childbearing potential and female participants within childbearing age were reluctant to use effective contraception from the time of signing the informed consent to 6 months after cell therapy; 26. Subjects assessed as inappropriate to participate in this clinical trial by investigator.